Enhanced potency of immunotherapy against B‐cell precursor acute lymphoblastic leukemia by combination of an Fc‐engineered CD19 antibody and CD47 blockade

Enhanced potency of immunotherapy against B‐cell precursor acute lymphoblastic leukemia by combination of an Fc‐engineered CD19 antibody and CD47 blockade

Abstract CD19‐directed immunotherapy has become a cornerstone in the therapy of B‐cell precursor acute lymphoblastic leukemia (BCP‐ALL). CD19‐directed cellular and antibody‐based therapeutics have entered therapy of primary and relapsed disease and contributed to improved outcomes in relapsed diseas...

Full description

Bibliographic Details
Main Authors: Denis M. Schewe, Fotini Vogiatzi, Ira A. Münnich, Tobias Zeller, Roland Windisch, Christian Wichmann, Kristina Müller, Hilal Bhat, Elisa Felix, Dimitrios Mougiakakos, Heiko Bruns, Lennart Lenk, Thomas Valerius, Andreas Humpe, Matthias Peipp, Christian Kellner
Format: Article
Language:English
Published: Wiley 2024-02-01
Series:HemaSphere
Online Access:https://doi.org/10.1002/hem3.48

Internet

https://doi.org/10.1002/hem3.48

Similar Items